Fundraising FoxGain Therapeutics
NASDAQ: GANXBethesda, US · Founded 2020 · 3 known investors
Find your way into Gain Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Anders Hove to introduce you to Gene Mack
You →Anders · together at Edge Therapeutics, Inc. →Gene
Sign up to find every way you can get introduced to Gain Therapeutics
- Your email: who you already know at Gain Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Gain Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
Founders & leadership
Board
Investors · 3
How we know: the S-1 prospectus · Not right? Tell us
How we know: TiVenture SA's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 of 2 rounds · 2019–2020
▶$10MraisedJul 2020 · 48 investors · BiotechnologyRule 506(b)
- Khalid IslamDirector
- Marianne BjordalDirector
- Jeffrey RileyDirector
- Lorenzo LeoniDirector
- Eric I. RichmanExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $50K
- Sales commissions
- $800K
- Placement agents
- Tribal Capital Markets, LLC
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 1
Companies working in the same space as Gain Therapeutics.
In the news
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conferencefinance.yahoo.com · Aug 2026Frequently asked questions
- What does Gain Therapeutics do?
- Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
- Who are Gain Therapeutics's investors?
- Gain Therapeutics's investors include 3B Future Health Fund, TiVenture SA, Allele Capital Partners.
- How much funding has Gain Therapeutics raised?
- Gain Therapeutics has disclosed $10M raised across 1 of its 2 known rounds.
- Where is Gain Therapeutics headquartered?
- Gain Therapeutics is headquartered in Bethesda, US.